Christopher Booth, MD

Christopher Booth
  • Principal Investigator, CCE Division
  • Level 2, Queen's Cancer Research Institute
  • Kingston, Ontario
  • K7L 3N6
  • Telephone: 613-533-6000 extension 78558
  • E-Mail:

Faculty Bio

  • Member, Division of Cancer Care and Epidemiology, Cancer Research Institute, Queen's University
  • Medical Oncologist
  • Clinician-Scientist, Cancer Centre of Southeastern Ontario
  • Associate Professor, Departments of Oncology and Medicine, Queen's University
  • Canada Research Chair in Population Cancer Care


Dr. Booth is a Medical Oncologist and Associate Professor in the Department of Oncology at Queen's University. He holds the Canada Research Chair in Population Cancer Care.  Dr. Booth leads a program of health services and outcomes research specifically related to the use of systemic therapy for cancer. His research program is funded by CIHR, CFI, CCSRI and Cancer Care Ontario. As a junior investigator he was awarded an inaugural Cancer Care Ontario Chair in Health Services Research. Since joining CCE in 2008 Dr. Booth’s research team has developed population-level chemotherapy databases for non-small cell lung cancer, bladder cancer, and colorectal cancer. These databases incorporate chemotherapy treatment records from all provincial cancer centres, New Drug Funding Program data from CCO and chemotherapy billing data from the provincial health insurance plan. These data-sets have subsequently been linked to the CCE existing database to permit population-based studies of the use of chemotherapy, similar to those that we have done previously with radiotherapy.   Specific objectives of Dr. Booth’s research program are to evaluate the effectiveness of new therapies in the general population, assess adherence to treatment guidelines, and to explore issues of access to, and quality of, cancer care in medical oncology.  Having completed a 2-year research fellowship at NCIC-Clinical Trials Group, Dr. Booth also has interest in the design, implementation, and interpretation of randomized clinical trials. He is the Study Co-Chair of NCIC CTG CO21, an international randomized trial evaluating the role of exercise in patients with early stage colon cancer.

Current Interests

  • Uptake and outcomes of novel anti-cancer therapies in Ontario, specifically related to bladder cancer, non-small cell lung cancer and colorectal cancer.
  • Methodology and interpretation of randomized clinical trials (RCTs) in medical oncology.
  • The role of exercise in cancer survivors.


Dr. Booth's publications are available on PubMed.

Last Modified: 2015-12-08